Wastewater Surveillance for Xylazine in Kentucky
AJPM Focus · 2024-06 · 3 (3) · 100203
DOI: 10.1016/j.focus.2024.100203 ↗Kurz gefasst
Fachartikel in der Zeitschrift AJPM Focus, 2024-06. Verfasst von Chris Delcher und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Kentucky, Lexington, Kentucky. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIDA NIH HHS, National Institutes of Health, National Institute of Justice.
Abstract (Originalsprache)
Introduction
In the U.S., xylazine, the veterinary non-opioid sedative, has emerged as a major threat to people who use illicitly manufactured fentanyl and other drugs. The aim of this study was to compare wastewater detection of xylazine with other public health and safety surveillance data from 2019 to 2023 in Kentucky.
Methods
Wastewater samples from 5 rest areas, 2 truck weigh stations, and 4 wastewater treatment plants were tested for xylazine. Wastewater xylazine positivity rates were compared with xylazine-positive submission rates from the National Forensic Laboratory Information System and Kentucky's fatal overdoses in 6-month periods (Period 1=January-June; Period 2=July-December).
Results
Xylazine was detected in 61.6% (424 of 688) of daily wastewater samples from roadway sites/wastewater treatment plants. For roadways, detection increased from 55% (Period 1, 2021) to 94% (Period 1, 2023), and wastewater treatment plants had an overall detection of 25.8% (n=66 samples, Periods 1 and 2, 2022). Increasing roadway positivity corresponded to trends in National Forensic Laboratory Information System xylazine-positive submission rates: from 0.19 per 1,000 submissions (Period 1, 2019) to 2.9 per 1,000 (Period 2, 2022, latest available). No deaths from xylazine were reported publicly in Kentucky, although this study's authors identified 1-4 deaths (true count suppressed) in the overdose surveillance system, which, in back-of-the-envelope comparisons with other states, is far fewer than expected.
Conclusions
Wastewater signals indicate broad geographic exposure to xylazine in Kentucky, yet health outcomes data suggest otherwise. These findings may inform regional, national, and international efforts to incorporate wastewater-based drug surveillance. Harm-reduction activities along roadways and other suitable locations may be needed.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute for Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Kentucky, Lexington, Kentucky.
- Department of Health Management & Policy, College of Public Health, University of Kentucky, Lexington, Kentucky.
- Department of Mechanical and Aerospace Engineering, University of Kentucky, Lexington, Kentucky.
- Department of Biomedical Engineering, University of Kentucky, Lexington, Kentucky.
- Department of Family and Community Medicine, University of Kentucky, Lexington, Kentucky.
- Department of Chemistry, Murray State University, Murray, Kentucky.
Förderung
- NIDA NIH HHS
- National Institutes of Health
- National Institute of Justice
Zitieren
APA
Delcher, C., Quesinberry, D., Torabi, S., Berry, S., Keck, J. W., Rani, A., & Subedi, B. (2024). Wastewater Surveillance for Xylazine in Kentucky. AJPM Focus, 3(3), 100203. https://doi.org/10.1016/j.focus.2024.100203
Vancouver
Delcher C, Quesinberry D, Torabi S, Berry S, Keck JW, Rani A, et al. Wastewater Surveillance for Xylazine in Kentucky. AJPM Focus. 2024;3(3):100203. doi:10.1016/j.focus.2024.100203
BibTeX
@article{Delcher2024,
author = {Delcher, Chris and Quesinberry, Dana and Torabi, Soroosh and Berry, Scott and Keck, James W and Rani, Abhya and Subedi, Bikram},
title = {Wastewater Surveillance for Xylazine in Kentucky},
journal = {AJPM Focus},
year = {2024},
volume = {3},
number = {3},
pages = {100203},
doi = {10.1016/j.focus.2024.100203}
}
EUVIMED